ArticleFrontiers in immunology2026
Tislelizumab-induced myositis antibody-negative myasthenia gravis in patients with urothelial carcinoma: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tislelizumab, an immune checkpoint inhibitor, is widely used in the treatment of various malignancies; however, its immune-related adverse events(irAEs) require careful attention. Here, we report a case of a patient with recurrent urothelial carcinoma who developed myositis and myasthenia-like manifestations after receiving tislelizumab, despite negative myasthenia-associated antibodies. The patient's symptoms gradually alleviated following treatment with corticosteroids and intravenous immunoglobulin. To our knowledge, antibody-negative myasthenia gravis associated with tislelizumab has been scarcely documented. This case highlights that in patients receiving tislelizumab, early pharmacological intervention should be considered when typical myasthenia-like manifestations occur, even in the absence of antibody positivity, emphasizing the importance of prompt recognition and timely treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.